This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Infinity Reports Updated Phase 1 Data Of IPI-145 In Indolent Non-Hodgkin Lymphoma At ASH Annual Meeting

Infinity is currently enrolling patients in DYNAMO, a Phase 2 study evaluating the safety and efficacy of IPI-145 in approximately 120 patients with refractory iNHL whose disease is refractory to radioimmunotherapy or to both rituximab and chemotherapy and who have progressed within six months of receiving their last therapy. The primary endpoint of the study is response rate according to the International Working Group (IWG) criteria. 1

Updated Phase 1 Data in Patients with iNHL

Updated Phase 1 data in 15 patients with relapsed/refractory iNHL who received IPI-145 at doses ≤ 25 mg BID were included in a poster presentation, “Treatment with the potent PI3K-delta,gamma inhibitor, IPI-145, is associated with rapid decreases in specific cytokines, chemokines and matrix metalloproteinases in the serum of patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma” (Abstract #1633).

Data showed that IPI-145 was clinically active, with a 73 percent overall response rate (11 of 15 evaluable patients) and a 20 percent complete response rate (3 of 15 patients). Eight patients (53 percent) remain progression-free for over one year.

IPI-145 was generally well tolerated, and the majority of side effects were low-grade, asymptomatic and transient. The most common ≥ Grade 3 side effects were increases in ALT or AST (two liver enzymes) (38 percent), neutropenia (31 percent) and diarrhea (13 percent).

Translational Data in iNHL and CLL

Additionally, researchers today presented new translational data supporting the rationale for studying IPI-145 in both iNHL and CLL (Abstract #1633). Pharmacodynamic data evaluating serum cytokines, chemokines and metalloproteinases (molecules known to play key roles in the interaction between malignant B-cells and the surrounding microenvironment) showed that IPI-145 rapidly decreased the levels of several of these molecules in the serum of both iNHL and CLL patients. These data provide a potential mechanistic rationale for the clinical activity of IPI-145 observed in both iNHL and CLL and support the use of the 25 mg BID dose in clinical studies in both iNHL and CLL.

2 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs